KoBioLabs
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
KoBioLabs develops drugs that work by modifying the human microbiome, the community of bacteria and other microorganisms that naturally live in the body and influence health.
It is a clinical-stage biotech listed on KOSDAQ, Korea's tech-focused stock exchange, targeting conditions including immune, metabolic, and neurological diseases. The company handles the full drug-development process in-house, from candidate discovery through clinical trials, and has built a proprietary drug-discovery platform called Smartiome, which it is advancing with AI and multi-omics data.
Summary is AI-generated and may contain errors · figures from DART filings
KoBioLabs claims to have initiated the first global clinical trials for a microbiome-based drug originating in Korea, covering two functional materials for immune diseases.
KoBioLabs in five facts
What does KoBioLabs do?
KoBioLabs develops drugs that work by modifying the human microbiome, the community of bacteria and other microorganisms that naturally live in the body and influence health.
Where is KoBioLabs listed and in which sector?
KoBioLabs (Korean name: 고바이오랩) trades under KRX code 348150 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is KoBioLabs?
Its market capitalisation was US$41.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were KoBioLabs's latest annual revenue and operating profit?
For fiscal year 2025, KoBioLabs reported revenue of US$52.3M, an operating loss of US$7.3M and a net loss of US$5.3M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 1.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.